Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 898Lymphoid 481Myeloid 154Classical hematology 41Sarcoma 24Plasma cell 20CNS 13Dermatologic 7Tumor-Agnostic 4Other solid neoplasm 2Other 1Genitourinary 1Breast 1

Conditions

Neoplasms 2Neoplasm, Residual 2Neoplasm Metastasis 1

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Cytarabine × Tumor-Agnostic × Clear all
NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting
472 enrolled
Tumor-Agnostic

Neoplasms

NCT05372536 2024-11-29

INTACTatHome

Rigshospitalet, Denmark

Phase NA Completed
15 enrolled
Tumor-Agnostic

Neoplasms

NCT05601830 2024-11-06

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Institute of Hematology & Blood Diseases Hospital, China

Phase 1 Terminated
1 enrolled
Tumor-Agnostic

Neoplasm, Residual

NCT02067143 2021-09-08

LAL1913

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2 Completed
204 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡